Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408531 · ClinicalTrials.gov registry record · NA
LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
A NA study, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
NCT07408531 is a NA study that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 2,500 participants.
The verdict
NCT07408531, a NA study, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.
Interventions
- DIAGNOSTIC_TEST Sybil Artificial Intelligence (AI) screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2038-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07408531
The ClinicalTrials.gov registry entry for NCT07408531 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sybil Artificial Intelligence (AI) screening is the first listed.
NCT07408531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07408531 about?
NCT07408531 is a clinical study titled "LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)". This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (b...
What is the current status of trial NCT07408531?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2026-03-12. Estimated completion is 2038-02.
What interventions are being tested in trial NCT07408531?
The interventions under investigation include: Sybil Artificial Intelligence (AI) screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07408531?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.